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Background: Hyperemesis gravidarum (HG) characterized by excessive nausea and vomiting in early pregnancy, is
reported to be associated with increased risks for low birthweight (LBW), preterm birth (PTB), small-for-gestational-age
(SGA) and perinatal death. Conflicting results in previous studies underline the necessity to study HG’s potential effect
on pregnancy outcomes using large cohorts with valid data on exposure and outcome measures, as well as potential
confounders. This study aims to investigate associations between HG and adverse pregnancy outcomes using the
Norwegian Mother and Child Cohort Study (MoBa).
Methods: All singleton pregnancies in MoBa from 1998 to 2008 were included. Multivariable regression was used to
estimate relative risks, approximated by odds ratios, for PTB, LBW, SGA and perinatal death. Linear regression was
applied to assess differences in birthweight and gestational age for children born to women with and without HG.
Potential confounders were adjusted for.
Results: Altogether, 814 out of 71,468 women (or 1.1%) had HG. In MoBa HG was not associated with PTB, LBW or
SGA. Babies born to women with HG were born on average 1 day earlier than those born to women without HG;
(−0.97 day (95% confidence intervals (CI): -1.80 - -0.15). There was no difference in birthweight when maternal weight
gain was adjusted for; (23.42 grams (95% CI: -56.71 - 9.86). Babies born by women with HG had lower risk for having
Apgar score < 7 after 1 minute (crude odds ratio was 0.64 (95% CI: 0.43 - 0.95)). No differences between the groups for
Apgar score < 7 after 5 minutes were observed. Time-point for hospitalisation slightly increased differences in
gestational age according to maternal HG status.
Conclusions: HG was not associated with adverse pregnancy outcomes. Pregnancies complicated with HG had a
slightly shorter gestational length. There was no difference in birth weight according to maternal HG-status. HG was
associated with an almost 40% reduced risk for having Apgar score < 7 after 1 minute, but not after 5 minutes. The
clinical importance of these statistically significant findings is, however, rather limited.
Keywords: Hyperemesis gravidarum, The Norwegian Mother and Child Cohort Study, Birth weight, Gestational age,
Preterm birth, Low birthweight, Small for gestational age, Apgar score, Perinatal death, Maternal weight gainBackground
Most women experience nausea and vomiting in early
pregnancy (NVP) [1]. In contrast, hyperemesis gravidarum
(HG) is a potentially life-threatening condition that occurs
in between 0.8% and 3.2% [2,3]. The 10th edition of Inter-
national Classification of Diseases (ICD 10) differentiates* Correspondence: ase.vigdis.vikanes@fhi.no
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reproduction in any medium, provided the orbetween mild (O21.0) and severe forms of HG (O21.1) [4].
The underlying mechanisms for HG remain unknown, al-
though previous research has suggested genetic factors to
be involved [5]. It is not yet clear whether maternal genes
or environmental factors are the main contributing fac-
tors. Increased levels of human chorionic gonadotropin
(hCG), oestrogen and leptin have been found to be associ-
ated with HG, as have increased levels of fetal DNA in
maternal blood; the latter indicating damage of the feto-
maternal barrier [1,6-8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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birthweight (LBW), preterm birth (PTB), small-for-
gestational-age (SGA), perinatal death and prolonged
stay in hospital for the new-born infant [9-12]. A recent
meta-analysis on HG and pregnancy outcomes, compris-
ing 13 case–control studies, 10 cohort studies and one
cross-sectional study, reported that HG was associated
with a 30% increase in risk for PTB and SGA, and a 40%
increase in risk for LBW [13]. A Dutch historical cohort
study among 1.2 million singleton births found HG to
increase the risk for PTB by 18%, but did not find HG
associated with SGA and LBW [14]. The same study,
however, did report a slight difference in birthweight
among children born to women with and without HG
[14]. In contrast, an Canadian cohort study of 156,000
singleton pregnancies reported that women with HG
gaining less than 7 kg during pregnancy had a threefold
increase in risk for PTB, an almost threefold increase in
risk for LBW and a fivefold increase in risk for a 5 mi-
nute Apgar score < 7 [9]. For women with HG and
weight gain ≥ 7 kg, there was no increase in risk for ad-
verse pregnancy outcomes. An American cohort study
among 520,000 live births found that infants of women
with HG had significantly lower birthweight and were
more likely to be SGA [11].
Conflicting results in previous studies can be explained
by heterogeneity of methods, definitions and confounders,
in addition to the fact that most of the evidence still comes
from case–control studies. Based on this, there is a need
to study HG’s potential effect on pregnancy outcomes
using large cohorts with valid data on both exposure and
outcome measures as well as potential confounders. The
aim of our study is therefore to explore associations be-
tween HG and adverse pregnancy outcomes using the
Norwegian Mother and Child Cohort Study (MoBa) com-
prising 108,000 births.
Methods
Population under study
This study is a subproject in MoBa. The recruitment to
MoBa occurred from 1998 to 2008. MoBa’s target popula-
tion consisted of all women attending antenatal care in
Norway, and the participation rate was about 40% [15].
Women were sent an invitation to participate and a writ-
ten consent form simultaneously as their appointment for
the routine second trimester ultrasound. Our analyses are
based on three questionnaires, one received in pregnancy
week 13–17 (Q1), one in week 30 (Q3) and one four to six
months after birth (Q4) [16]. Q1 provided background
factors, exposures and health variables. Q3 included infor-
mation on health during pregnancy. In Q4 the main
themes were maternal health around the birth and the
time immediately after. English translations of the ques-
tionnaires can be found at http://www.fhi.no/moba. Thestudy has been approved by the Data Inspectorate and the
Regional Committee for Medical and Health Research
Ethics. The birth record from the Medical Birth Registry
of Norway (MBRN) is a part of the MoBa database. In
Norway, notification of all live births and stillbirths from
the 12th week of gestation is mandatory and information
has to be sent to MBRN within one week after delivery
[17]. We included singleton pregnancies only.
We excluded records with missing data on birthweight
(n = 63), on gestational age (n = 349), on Apgar scores
after 1 and 5 minutes (n = 194 and n = 181), on body mass
index (BMI) (n = 13,556), on education (n = 4,620), and on
smoking habits (n = 1,524). There was no missing data on
maternal age and parity. Moreover, we also excluded chil-
dren born < 22nd gestational week (n = 7) and ≥ 43rd ges-
tational week (n = 231) and those weighing < 500 grams
(n = 10) or ≥ 6000 grams (n = 7). Women with implausible
values on weight and height were excluded; those
reporting height < 120 cm (n = 198), missing height (n =
795) and those weighing less than 40 kg (n = 47) or more
than 150 kg (n = 11) or missing weight (n = 1975) or
reported weight gain during pregnancy to be > 50 kg (n =
35) or < −20 kg (n = 43). No one reported to be taller than
200 cm. The final sample consisted of 71,468 pregnancies
or 78.4% of the sample.
Variables
Given the structure of the questionnaires, the exposure
variable, HG, was defined as long-lasting nausea and
vomiting in pregnancy starting before the 25th gestational
week and necessitating hospitalisation as reported in Q3
in MoBa. Sub-analyses have previously shown that 74%
were first hospitalised during first trimester, and 25% were
first admitted later in pregnancy [18]. These findings are is
in line with a recent study from Sweden on HG and preg-
nancy outcomes based on hospital data [19].
The main outcome variables were gestational age, birth-
weight, LBW defined as birthweight < 2500 grams, PTB
defined as gestational age < 37 gestational weeks, SGA de-
fined as birthweight below the 10th percentile for the ges-
tational age, perinatal death defined as death during the
perinatal period (lasting from ≥ 22nd gestational week
until the 7th day after birth), Apgar score after 1 minute
and after 5 minutes; all obtained from MBRN.
Data on pre-pregnant BMI, parity and education were
obtained from Q1. Information about maternal weight
gain during pregnancy was obtained from Q1 and Q4.
Data on smoking in pregnancy was obtained from Q1 and
Q3, where the women registered whether they smoked on
a daily basis, occasionally or did not smoke. Information
on concomitant diseases such as asthma, diabetes 1, thy-
roid disorders, depression, anxiety, other psychological
problems, anaemia, vitamin B12 deficiency and anorexia
was obtained from Q1. This questionnaire included a
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prefaced with ‘did you have any of these diseases or health
problems before or in pregnancy?’ The diseases men-
tioned above were selected since previous studies have
showed associations with HG [1,20,21].
Maternal age was categorised into 5 groups: younger
than 20 years, 20–24 years, 25–29 years, 30–34 years and
35 years and older. By parity, women were dichotomised
into nullipara and multipara. A proxy for socioeconomic
status (SES) was the woman’s length of education in years
categorised into 4 groups: < 12 years, 12 years, 13–16 years
and ≥ 17 years. Smoking before pregnancy was categorized
as no smoking and smoking including both daily and oc-
casional smoking. BMI was grouped into 4 categories: <
18.5 kg/m2, 18.5-24.9 kg/m2, 25.0-29.9 kg/m2 and ≥
30.0 kg/m2. Maternal weight gain during pregnancy was
categorised < 0 kg, 0–6.9 kg, 7.0-14.9 kg, 15.0-19.9 kg, ≥
20.0 kg and missing. Time-point for hospitalisation was
divided into three groups: first trimester, second trimester
and first-and-second trimester. Concomitant diseases,
such as diabetes, Type 1 diabetes, thyroid diseases, depres-
sion, anxiety, other psychological problems, anaemia, vita-
min B12 deficiency and anorexia were dichotomised into
no and yes for each disease.
Statistical analyses
Since 12,460 women contributed with more than one
pregnancy, some of the data cannot be considered to be
independent. Consequently, all analyses were done with
generalized estimation equations (GEE) employing an in-
dependent correlation structure to obtain valid standard
errors. Associations between HG and LBW, PTB, SGA
and Apgar score < 7 after 1 minute and 5 minutes were
studied by GEE. Crude (cOR) and adjusted (aOR) odds ra-
tios with 95% confidence intervals (CI) were calculated. In
addition, the effects of HG on birthweight and gestational
age as continuous variables were studied by multiple lin-
ear regressions.
Three sets of adjustments were performed in multivar-
iable analyses; the first included socio-demographic data
as well as induction and gestational age for birthweight
and Apgar score after 1 and 5 minutes. The second ad-
justment included concomitant medical conditions.
Thirdly, we adjusted for maternal weight gain during
pregnancy.
No interactions were found between HG and any other
variable, suggesting no heterogeneity of the effect of HG
on pregnancy outcomes. All analyses were performed using
R version 2.12.1 with library geepack for GEE analyses.
Results
Altogether, 814 out of 71,468 women (1.1%) had HG.
Women with HG were younger, had less education and
had to a larger extent been non-smokers before pregnancy.They had lower or higher pre-pregnancy BMI compared to
those without HG. A higher proportion of women with HG
gained less weight during pregnancy than those without
HG (Table 1).
When maternal age, parity, BMI, education, smoking
habits, gestational age, induction, concomitant diseases
and maternal weight gain was adjusted for, there was no
difference in birth weight according HG-status (Table 2).
In contrast, babies to women with HG they were on aver-
age born one day earlier compared to those born to
women without HG.
Slightly more than 60% of women with HG were
hospitalised during first trimester only, whereas approxi-
mately 20% were admitted during second trimester. Time-
point for hospitalisation did not influence birth weight or
gestational age when potential confounders adjusted for
(Table 3).
Hyperemesis was not associated with PTB, SGA or LGA
(Table 4). Children of women with HG had, however,
lower risk of having Apgar score < 7 after 1 minute (cOR
was 0.63 with 95% confidence interval (CI): 0.42-0.93).
There was no difference in odds ratios for Apgar score < 7
after 5 minutes. Adjustment for confounders did not
change these estimates. There were 167 cases of perinatal
death, but none of the mothers of cases had HG. Time-
point for hospitalisation due to HG did not influence the
risks for adverse pregnancy outcomes (data not shown).
Women with HG gained on average 12.7 kilos during
pregnancy, compared to 14.9 kilos for women without HG.
Discussion
The main finding of our study is that HG requiring hospi-
talisation was not associated with increased risks for PTB,
LBW or SGA. Pregnancies complicated with HG had a
slightly shorter gestational length. There was no difference
in birth weight according to maternal HG-status. Time-
point for hospitalisation did not influence birthweight or
gestational age. Moreover, HG was associated with lower
risk for having Apgar score < 7 after 1 minute, whereas
there was no difference in risks for Apgar < 7 score after
5 minutes. The clinical relevance of these findings is, how-
ever, limited.
Strengths and limitations
The major strength of our study is that it has data on the
main exposure and confounders from a large, nationwide
pregnancy cohort. Furthermore, previous research has
proven that the validity of the data in MoBa to be high
[22-24]. Information on pregnancy outcomes were ob-
tained from MBRN comprising data validity earlier de-
scribed as sufficient for large scale epidemiologic research
[25,26]. Altogether, the two different sets of data provide a
unique opportunity to study possible effects of HG on
pregnancy outcomes. To some extent MoBa suffers from
Table 1 Prevalence of hyperemesis gravidarum (HG) with
95% confidence intervals (95% CI) according to
background characteristics (N = 71,468)
n (%) HG (%) (95% CI)
Maternal age
< 20 years 816 (1.1) 2.8 (2.7-2.9)
20-24 years 7674 (10.7) 1.9 (1.8-2.0)
25-29 years 25267 (35.3) 1.1 (1.1-1.2)
30-34 years 27064 (37.9) 0.9 (0.9-1.0)
≥ 35 years 10647 (14.9) 1.0 (0.9-1.0)
Parity
Primipara 33408 (46.8) 1.1 (1.0-1.1)
Multipara 38060 (53.2) 1.2 (1.1-1.3)
Body mass index
< 18.5 (kg/m2) 1325 (1.9) 2.0 (1.9-2.1)
18.5-24.9 (kg/m2) 47390 (66.3) 1.0 (0.9-1.1)
25.0-29.9(kg/m2) 15727 (22.0) 1.4 (1.3-1.5)
≥ 30.0 (kg/m2) 7026 (9.8) 1.5 (1.4-1.6)
Education
< 12 years 14168 (19.8) 1.6 (1.5-1.7)
12 years 10438 (14.6) 1.4 (1.3-1.4)
13-16 years 29569 (41.4) 1.1 (1.0-1.1)
≥ 17 years 17293 (24.2) 0.8 (0.7-0.9)
Smoking habit
Non-smokers 65362 (91.5) 1.2 (1.1-1.3)
Smokers 6106 (8.5) 0.6 (0.5-0.7)
Weight gain during pregnancy
< 0 kg 565 (0.8) 5.9 (5.7-6.0)
0 - 6.9 kg 3708 (5.2) 2.3 (2.2-2.5)
7.0 - 14.9 kg 26360 (36.9) 1.1 (1.1-1.2)
15.0 - 19.9 kg 15239 (21.3) 0.7 (0.7-0.8)
≥ 20 kg 8126 (11.4) 1.1 (1.0-1.1)
Missing 17470 (24.4) 1.1 (1.0-1.2)
Table 2 Differences in birthweight and gestational age for of
gravidarum (N = 71,468)
N =
71,468
Mean Crude estimate Ad
β [95% CI] β
Birthweight
No hyperemesis (HG) 70,654 3602 gram 1 Reference 1
HG 814 3567 gram −34.46 (−72.84 - 3.93 ) −4
Gestational age
No HG 70,654 279.7 days 1 Reference 1
HG 814 278.0 days −1.68 (−2.53- -0.84 ) −1
*Adjusted for maternal age, parity, BMI, education and smoking habits.
**Additional adjustment for gestational age and induction.
***Additional adjustment for asthma, diabetes 1, thyroid disease, depression, anxiety
****Adjustment for maternal weight gain.
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education, smoke less and are less likely to be immigrants
compared to the Norwegian population at large [27].
Nilsen et al. reported in a study on MoBa and selection
bias that the prevalence of conditions could be affected by
selection bias, but that there was no evidence that the se-
lection bias affected the associations studied [27]. If the val-
idity of the observed association between HG and
pregnancy outcomes should be affected by selection bias, it
would require differential selection of participants related
to both HG and pregnancy outcomes studied, something
not considered in this study. Thus it is inconceivable that
data on pregnancy outcomes from MBRN, compulsory
obtained after recruitment, could be directly associated
with selection to the study. Since all citizens of Norway
have access to hospitals free of charge, there should be lit-
tle selection to in-patient care based on economic re-
sources of the single patient. Furthermore, as HG is
associated with ethnicity, it is unfortunate that we did not
have information on maternal country of birth in MoBa.
However, only 5.6% of the participants reported not to
have Norwegian as mother tongue. Adjustment for mother
tongue did not influence our estimates.
Comparison with other studies
Unlike the previously mentioned meta-analysis including
more than 50% case–control studies, we did not find
HG to be associated with an increased risk of PTB, LBW
and SGA [13]. The heterogeneity described in the meta-
analysis is, however, a consequence of methodological as
well as clinical differences between the studies. The clin-
ical heterogeneity was mainly related to difficulties in
defining HG. The use of different diagnostic criteria may
reflect that so far there is no universally accepted defin-
ition of HG, indicating that other pregnancy related con-
ditions may have been confused with HG. Some studies
had used hospital admission as a criterion, others the
8th or 9th version of the International Classification of
Disease (ICD) or Fairweather’s diagnostic criteria fromfspring of mothers with and without hyperemesis
justed estimate Adjusted estimate Adjusted estimate
[95% CI]* β [95% CI]*** β [95% CI]****
Reference 1 Reference 1 Reference
6.89 (−80.53 -13.26)** −47.57 (−79.92- -13.21)** −23.42 (−56.71- 9.86 )**
Reference 1 Reference 1 Reference
.50 (−2.34- -0.67 ) -1.38 (−2.21- -0.55) -0.97 (−1.80- -0.15 )
, other psychological problems, anorexia, anaemia and vitamin B12 deficiency.
Table 3 Differences in birth weight and gestational age with 95% confidence intervals according to hospitalisation
time-points (N = 71,425*)
N = 71,425 Mean Crude estimate Adjusted estimate Adjusted estimate Adjusted estimate
β (95% CI) β (95% CI)** β (95% CI)**** β (95% CI)*****
Birth weight
No hyperemesis (HG) 70654 3602 gram 1 1 1 1
HG 1. Trimester 484 3591gram −10.67 (−60.2 – 38.83) −30.57 (−74.57 – 13.42) *** −31.55 (−75.42 – 12.32) *** −15.32 (−58.96 – 28.31) ***
HG 2. Trimester 173 3506 gram −95.29 (−178.4 – -12.18) −85.68 (−155.8 – -15.61) *** −85.86 (−155.2 – -16.49) *** −49.15 (−117.8 – 19.49) ***
HG 1. and 2. trimester 114 3563 gram −39.02 (−139.9 – 61.83) −91.20 (−176.9 – -5.48) *** −92.46 (−178.2 – -6.72) *** −51.06 (−138.2 – 36.11) ***
Gestational age
No HG 70654 280 days 1 1 1 1
HG 1. Trimester 484 278 days −1.29 (−2.31 – -0.28) −1.12 (−2.15 – -0.10) −1.05 (−2.07 – -0.03) −0.79 (−1.80 – 0.23)
HG 2. trimester 173 278 days −2.10 (−4.14 – -0.06) −1.90 (−3.91 – 0.10) −1.72 (−3.68 – 0.25) −1.08 (−3.04 – 0.88)
HG 1. and 2. trimester 114 277 days −2.56 (−4.89 – -0.24) −2.39 (−4.70 – -0.08) −2.22 (−4.53 – 0.09) −1.57 (−3.89 – 0.75)
* Women with missing data on time-point for hospitalisation were excluded (n = 43).
**Adjusted for maternal age, parity, BMI, education and smoking habits.
***Additional adjustment for gestational age and induction.
****Additional adjustment for asthma, diabetes 1, thyroid disease, depression, anxiety, other psychological problems, anorexia, anaemia and vitamin
B12 deficiency.
*****Adjustment for maternal weight gain.
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ketonuria and more than 5% weight loss compared to
prepregnancy weight [4,9,28]. Due to the structure of
MoBa’s questionnaires, HG was in our study defined as
long-lasting nausea and vomiting in pregnancy starting
before the 25th gestational week which required hospital-
isation. In line with previous studies, more than 70% of
the women with HG in MoBa were hospitalised during
the first 12 weeks [18,19]. In contrast to the recent Swed-
ish publication, time-point for hospitalisation did not in-
fluence the estimates in our study [19]. In Norway, only
women with HG and metabolic disturbances are being
hospitalised, indicating that our sample includes severe
HG only (or ICD 10 code O21.1). This assumption sug-
gests that our sample was not diluted with other preg-
nancy related conditions, such as the more common
“nausea and vomiting in pregnancy” (NVP), which up to
90% of all pregnant women suffer from [29]. However, di-
lution may have been a problem in the large study based
on the Dutch Perinatal Registry, describing that 34% was
having HG diagnoses set by midwifes in the absence of
hospitalisation [14]. The prevalence of HG in the Dutch
study was 0.2%, which is lower than in other European
studies. The authors questioned the quality of their own
dataset, suggesting an underreporting of the disease. Also;
HG was associated with near to 40% increase in risk for
PTB, and about 10% increase in risk for SGA [14]. When
maternal characteristics, such as age, parity, ethnicity,
socio-economic status and concomitant diseases were ad-
justed for, only PTB remained associated with HG. How-
ever, several relevant confounders, such as BMI and
smoking, were not adjusted for. Another study based onSwedish births between 1973 and 1982 reported a HG
prevalence of 0.3% [30]. These women were more likely to
give birth before 38 gestational weeks and to deliver chil-
dren with LBW. The abovementioned American cohort
study among more than 500,000 live births found a HG
prevalence of 0.5%, where HG was associated with SGA
and LBW [11]. The two latter studies reported univariate
analyses only.
In contrast, a Canadian historical birth cohort study of
156,000 pregnancies, using hospital admission before the
24th gestational week as a diagnostic criterion for HG,
found a prevalence of HG of 1.0%, which is similar to our
study [9]. The HG diagnosis was based on Fairweather’s
diagnostic criteria, and information on most relevant con-
founders was available. Unlike our study, HG was found
to be associated with an increased risk of PTB, LBW, SGA
and Apgar score < 7 after 5 minutes, but only for women
with maternal weight gain during pregnancy < 7 kg. The
relative risks were 3.0, 2.8, 1.5 and 5.0, respectively. In
MoBa 25% of the women in our study had missing data
on maternal weight gain. Since these women had signifi-
cantly higher risk of adverse pregnancy outcomes, we ad-
justed for maternal weight gain instead of stratifying
similar to the Canadian study. Additional sub-analysis,
where women with missing data on weight gain were ex-
cluded and the remaining sample was stratified according
to whether the women gained less than 7 kilos or 7 kilos
and more, did not change our estimates.
Maternal weight gain and body composition have, re-
gardless of maternal HG-status, been thoroughly investi-
gated as possible predictors for gestational age and birth
weight [31,32]. A recent metanalysis of 55 studies, 37
Table 4 Risk of adverse pregnancy outcomes with 95% confidence intervals according to hyperemesis gravidarum
(N = 71,468)
n
(%)
Prevalence (%)
(95% CI)
Crude odds ratio
(95% CI)
Adjusted odds ratio
(95% CI)*
Adjusted odds ratio
(95% CI)***
Adjusted odds ratio
(95% CI)****
Gestational age
< 37 weeks
3157
(4.4)
No hyperemesis (HG) 4.4 (4.3- 4.6) 1 Reference 1 Reference 1 Reference 1 Reference
HG 5.3 (5.1- 5.4) 1.21 (0.89-1.65) 1.18 (0.86-1.60) 1.15 (0.84-1.57) 1.02 (0.75-1.40)
Birthweight
< 2500 grams
1791
(2.5)
No HG 2.5 (2.4- 2.6) 1 Reference 1 Reference 1 Reference 1 Reference
HG 2.5 (2.3- 2.6) 0.98 (0.63-1.53) 0.80 (0.47-1.36)** 0.80 (0.47-1.35)** 0.72 (0.42-1.24)**
Small for
gestational age
6793
(9.5)
No HG 9.5 (9.3- 9.7) 1 Reference 1 Reference 1 Reference 1 Reference
HG 9.6 (9.4- 9.8) 1.01 (0.80-1.28) 1.10 (0.87-1.40) 1.11 (0.87-1.40) 1.01 (0.80-1.29)
Apgar score after
1 minute < 7
3553
(5.0)
No HG 5.0 (4.8-5.2) 1 Reference 1 Reference 1 Reference 1 Reference
HG 3.2 (3.1-3.3) 0.63 (0.42-0.93) 0.62 (0.42-0.93)** 0.62 (0.42-0.93)** 0.64 (0.43-0.95)**
Apgar score after
5 minutes < 7
848
(1.2)
No HG 1.2 (1.1-1.3) 1 Reference 1 Reference 1 Reference 1 Reference
HG 1.2 (1.1- 1.3) 1.04 (0.55-1.94) 1.07 (0.56-2.02)** 1.04 (0.55-1.97)** 1.11 (0.58-2.12)**
Perinatal death 167
(0.2)
No HG 0.2 (0.2- 0.3) — — — —
HG 0.0 (−−)
*Adjusted for maternal age, parity, BMI, education and smoking habits.
**Additional adjustment for gestational age and induction.
***Additional adjustment for asthma, diabetes 1, thyroid disease, depression, anxiety, other psychological problems, anorexia, anemia and vitamin B12 deficiency.
****Adjustment for maternal weight gain during pregnancy.
Vikanes et al. BMC Pregnancy and Childbirth 2013, 13:169 Page 6 of 8
http://www.biomedcentral.com/1471-2393/13/169cohort and 18 case–control including 3.5 million
women, reported that low total gestational weight gain
was associated with increased risks for PTB, LBW and
intrauterine growth retardation (IUGR) and lower mean
birth weight [31]. In this perspective, the associations
between HG and adverse pregnancy outcomes reported
in previous research may be explained by poor maternal
weight gain rather than the mother suffering from HG
[9,12]. Moreover, an American case–control study found
women with HG to gain on average 4.6 kg less during
pregnancy, and to deliver babies who weighed on aver-
age 291 grams less compared to those born from healthy
women [10]. In MoBa women with HG gained on aver-
age 2.2 kg less than women without HG, but their babies
did not have lower birth weight. However, they were
born on average one day earlier. In contrast, a Norwe-
gian institution-based case–control study reported that
the 175 women hospitalised with HG gained on average
5.1 kg less than women without HG, their babies to beborn 0.5 day earlier and weigh on average 138 grams less
[33]. Birthweight was positively associated with maternal
weight in early pregnancy, weight gain during pregnancy
and parity, but not HG. This is partly in line with our
study, where stepwise regression showed that differences
in birth weight between babies born to women with and
without HG disappeared when maternal weight gain was
adjusted for. In the other study, almost 50% of the cases
and more than 20% of controls had non-Norwegian
names, which is different from MoBa [33]. Immigrant
women in Norway are more likely to develop HG and
have higher risks of adverse pregnancy outcomes such as
IUGR and perinatal death [3,34,35]. It is not yet known
if immigrant women with HG have more severe symp-
toms and gain less weight during pregnancy compared
to ethnic Norwegians. Differences in results between the
studies might be explained by differences in ethnic back-
ground among the women included. The results of our
study may therefore not be generalisable for the total
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with adverse pregnancy outcomes, our results might re-
flect good antenatal care and treatment of women
hospitalised with HG participating in MoBa.
Whereas the 1 minute Apgar score reflects the immedi-
ate need for resuscitation, the 5 minute Apgar score has
more a prognostic value [36]. Most studies therefore report
Apgar score after 5 minutes, since this information is reck-
oned to be of higher clinical importance [37,38]. In our
study, the children of women with HG had about 40%
lower risk of Apgar score < 7 after 1 minute, but there was
no difference in risk for Apgar score < 7 after 5 minutes. It
is highly unlikely that this is an effect of corticosteroids ad-
ministered to relieve symptoms in women with refractory
HG during the first or second trimester [29,39]. Corticoste-
roids administered before 23rd gestational week is not
known to have any effect on the fetal lung [40]. Accord-
ingly, the 40% reduction of Apgar score in our study might
reflect underlying mechanisms for HG rather than conse-
quence of treatment. The clinical importance of this statis-
tical significant finding, however, is considered limited.
Although HG in our study did not have any negative
short-term consequences for the offspring, the possibility
for long-term consequences have barely been studied. Pre-
vious research has shown that metabolic changes in
women with HG might resemble those resulting from
starvation [41]. Given the fact that fetal undernutrion dur-
ing first trimester is associated with cardiovascular disease,
diabetes and schizophrenia in later life, HG may also influ-
ence disease patterns [41,42].
Conclusions
In MoBa HG requiring hospitalisation was not associated
with adverse pregnancy outcomes. Pregnancies compli-
cated with HG had slightly shorter gestational length.
However, there was no difference in birth weight
according to maternal HG-status. Additionally, HG was
associated with a decreased risk for delivering a child with
Apgar score < 7 after 1 minute, but no difference was ob-
served after 5 minutes. The clinical relevance of these sta-
tistically significant findings is rather limited, other than
comforting the mothers-to-be by informing them that HG
does not seem to increase the risk for PTB or having a
child with LBW and SGA or low Apgar scores.
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